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impairment of endothelium-dependent relaxation
through Akt/eNOS-dependent pathway
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Background: Recent studies have demonstrated a protective effect of osteocalcin (OCN) on glucose homeostasis and
metabolic syndrome. However, its role in vascular function remains unknown. This study investigated the contribution of
OCN to the pathogenesis of endothelial dysfunction in the thoracic aorta of apolipoprotein E-deficient (ApoE-KO) mice.
Methods: Eight-week-old ApoE–KO mice were given chow or high fat diet (HFD) for 12 weeks with or without daily
intraperitoneal injection of OCN. Intraperitoneal glucose tolerance test (IPGTT), insulin tolerance test (ITT),measurement of
serum lipid profiles and blood pressure were carried out. Endothelium-dependent relaxation (EDR) was measured by wire
myography. Human umbilical vein endothelial cells (HUVECs) were used to study the role of OCN on eNOS levels in vitro.
PI3K inhibitor (LY294002) and Akt inhibitor V were used ex-vivo to determine whether PI3K/Akt/eNOS contributes to the
beneficial effect of OCN for the vascular or not.
Results: Daily injections of OCN can significantly improve lipid metabolism, glucose tolerance and insulin sensitivity in
ApoE-KO mice. In ApoE-KO mice fed with HFD, the OCN-treated mice displayed an improved acetylcholine-stimulated
EDR compared to the vehicle-treated group. In addition, compared to vehicle-treated HUVECs, OCN-treated HUVECs
displayed increased activation of the Akt-eNOS signaling pathway, as evidenced by significantly higher levels of
phosphorylated Akt and eNOS. Furthermore, a similar beneficial effect of OCN on thoracic aorta was observed using
ex vivo organ culture of isolated mouse aortic segment. However, this effect was attenuated upon co-incubation with
PI3K inhibitor or Akt inhibitor V.
Conclusions: Our study demonstrates that OCN has an endothelial-protective effect in atherosclerosis through mediating
the PI3K/Akt/eNOS signaling pathway.
Keywords: ApoE knockout mice, Osteocalcin, Endothelium-dependent relaxation, PI3K/Akt/eNOS signaling pathway,
Metabolic syndrome, AtherosclerosisBackground
Osteocalcin (OCN), the most abundant noncollagenous
protein in bone, is an important clinical marker of bone for-
mation and bone turnover. Studies of OCN levels in pa-
tients with metabolic dysfunctions have revealed a close
correlation with perturbed OCN levels [1,2]. Loss- and gain-
of-function experiments in mice have identified systemic
roles of OCN in glucose, lipid and energy metabolism,* Correspondence: byq522@163.com
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unless otherwise stated.whereby the protein ultimately promotes pancreatic insulin
production and secretion [3,4]. Similarly, several recent
studies in humans have demonstrated independent inverse
correlations between serum OCN level and plasma glucose
concentration, dyslipidemia, and metabolic syndrome;
each of these clinical parameters are related to atheroscler-
osis, and are, therefore, risk factors for cardiovascular dis-
ease [5-8]. In addition, enhanced levels of OCN have been
detected proximal to calcified plaques of human and ro-
dent vascularization [9-11]. Taken together, these results
suggest a close relationship between OCN and vascular
disease.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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remains controversial. Results of a clinical trial which in-
vestigated the relationship between OCN and arterial stiff-
ness showed that serum OCN level was inversely
associated with brachial-ankle pulse-wave velocity in pa-
tients with T2DM [12]. Previous research by our group in-
dicated that an inverse association may exist between
serum OCN level and the severity of coronary atheroscler-
osis in Chinese men and with carotid intima-media thick-
ness in Chinese postmenopausal women [7,13]. Another
clinical study conducted by Li S, et al. also confirmed the
results mentioned above [14]. Moreover, the potential pro-
tective effect of OCN against development of vascular dis-
ease has been consistently evidenced in both in vitro
experiments and animal studies [15]. Nevertheless, a study
by Atsushi A, et al. concluded a negative result that they
thought serum osteocalcin did not show any relationship
with vascular calcification [16].
Endothelial dysfunction is an early step in the devel-
opment of atherosclerosis. It contributes to the initi-
ation and early progression of atherosclerosis. In
addition, endothelial dysfunction, as an independent
predictor of cardiovascular events, has been consist-
ently associated with obesity and the metabolic syn-
drome in a complex interplay with insulin resistance.
However, the specific contribution of OCN to vascular
dysfunction remains largely unknown. Thus, the current
study was designed to investigate the role and molecular
mechanism of OCN in endothelium-dependent relaxation
(EDR) by using a mouse model of atherosclerosis and cul-
tured human endothelial cells.Materials and methods
Antibodies and chemicals
Rabbit anti-mouse phosphorylated (P)-Akt (Ser473)
(1:1000 dilution), total-Akt (1:1000), P-endothelial nitric
oxide synthase (eNOS; Ser1177) (1:1000), total-eNOS
(1:1000), P-PI3K (1:1000), total-PI3K (1:1000) and GAPDH
(1:2500) were purchased from Cell Signaling Technology
(Danvers, MA, USA). OCN was obtained from Thermo
Fisher Scientific, Inc. (Waltham, MA, USA). Phenylephrine
(PE), acetylcholine (Ach), NG-nitro-L-arginine methyl ester
(L-NAME), sodium nitroprusside (SNP), phosphatidylino-
sitide (PI)3-kinase inhibitor LY294002, and protein kinase
B (Akt) inhibitor V were purchased from Sigma-Aldrich
(St. Louis, MO, USA) and dissolved in recommended sol-
vents. Dulbecco’s modified Eagle’s medium (DMEM), fetal
bovine serum and antibiotics were obtained from Gibico
(Gaithersburg, MD, USA). Insulin ELISA kit was offered
by Antibody and Immunoassay Service Center in Hong
Kong University. TNF-α, IL-1α, IL-12 p70 and IL-12
p40 ELISA kits were purchased from R&D Systems
(Minneapolis, Minnesota, USA).Cell culture
Human umbilical vein endothelial cells (HUVECs) were
isolated from fresh human umbilical veins (neonate
cords donated by the Shanghai Jiao Tong University
affiliated Sixth People’s Hospital, China) using 0.125%
trypsase and cultured in endothelial basal medium (EBM-
2; cc-3202, Lonza Group, Ltd., Basel, Switzerland) supple-
mented with 2% fetal bovine serum and various endothelial-
cell growth factors at 37°C in a 95% O2/5% CO2 humidified
incubator. Culture passages 2 through 4 were used for the
experiments.
Animals and in vivo study design
Male ApoE-KO mice established on a C57BL/6 genetic
background (7 weeks-old; 18 – 20 g) were purchased
from the Medical Research Center of Peking University
(Beijing, China). The mice were housed in filter-topped
cages under pathogen-free conditions with a 12-hour
light/dark cycle (darkness from 7:30 p.m. to 7:30 a.m.),
23 ± 1°C constant temperature, 55–60 humidity, and ad
libitum access to standard laboratory food and water. All
mice were acclimatized to the laboratory environment
for one week prior to experimentation. All experimental
protocols complied with institutional guidelines for the
humane treatment of laboratory animals. The protocol
was approved by the ethics committee of Shanghai Jiao
Tong University Affiliated Sixth People’s Hospital, fol-
lowing the priciples of the Declaration of Helsinki.
At 8 weeks-old, the mice were randomly selected for re-
ceipt of chow diet or high fat diet (HFD; 42% fat and
0.15% cholesterol [TD88137; Harlan Teklad, Madison,
WI, USA]) for 12 weeks, with or without daily (4:00 pm)
intraperitoneal (i.p.) injection of 10 μL/g OCN (at 3 ng/μL
freshly diluted in normal saline (0.9% NaCl; vehicle)). Body
weight was measured weekly by electronic balance.
Intraperitoneal glucose tolerance test (GTT) and Insulin
tolerance test (ITT)
After overnight fasting and i.p. injection of glucose
(1.5 g/kg body weight), tail vein blood sampling was car-
ried out at the indicated time points. Glucose and insu-
lin levels were measured by glucometer (ACCU-CHEK;
Roche Diagnostics Inc., Indianapolis, IN, USA) and
enzyme-linked immunosorbent assay, respectively. The
mouse insulin ELISA kit had intra- and interassay coef-
ficients of variation of 10% and 10%, respectively.
After 6 h of fasting and i.p. injection of insulin (0.5 U/
kg of Humulin; Eli Lilly, Inc., Indianapolis, IN, USA), tail
vein blood sampling was carried out at the indicated
time points. Blood glucose was measured as above.
Determination of blood parameters
All collected blood samples were stored at −80°C until
analysis. Fasting blood glucose (FBG) measurements were
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and 12 h fasting time points, prior to glucose or insulin
injection. After 12 weeks of experimental intervention
(20-week-old animals), serum lipid profiles were measured
enzymatically using an autoanalyser (7600–120 Automatic
Analyser, Hitachi Inc., Tokyo, Japan) and included detec-
tion of triglycerides (TG), total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C), and low-density
lipoprotein cholesterol (LDL-C). Serum levels of TNF-α,
IL-1α, IL-12 p70 and IL-12 p40 were measured by ELISA.
Measurement of blood pressure
Blood pressure measurements were made on 20-week-
old animals after the experimental intervention. Systolic,
mean, and diastolic blood pressures (BPs) were mea-
sured by a programmable sphygmomanometer (BP-98A;
Softron Co Ltd, Tokyo, Japan) using a tail-cuff method
described previously [17].
Measurement of vascular reactivity in isolated ApoE-KO
aortic strips
All mice were sacrificed after the 12th week of experi-
mental intervention, and the descending thoracic aorta
(2-mm long) was excised and immediately submerged in
oxygenated ice-cold Krebs solution (in mmol/L: 130
NaCl, 4.7 KCl, 1.6 CaCl2, 1.17 MgSO4 · 7 H2O, 14.9
NaHCO3, 1.18 KH2PO4, 0.026 EDTA and 5.5 glucose).
Changes in isometric tone of the aortic strips were re-
corded by wire myography (Danish Myo Technology,
Aarhus, Denmark). The strips were stretched to an opti-
mal baseline tension of 5 mN and allowed to equilibrate for
60 min prior to experimentation. Subsequently, the strips
were contracted with 60 mmol/L KCl and rinsed several
times in Krebs solution. Phenylephrine (PE; 10−5 M) was
added to produce a steady contraction. The EDR triggered
upon addition of increasing concentrations of acetylcholine
(ACh; 10−9 M to 10−5 M) were recorded.
In a separate set of experiments, aortic strips were incu-
bated with NG-nitro-L-arginine methyl ester (L-NAME;
10−4 M) for 30 min, followed by precontraction and deter-
mination of EDR. Relaxation response to sodium nitro-
prusside (SNP; 1 nM to 1 μM) was also investigated to
test the responsiveness of the vascular smooth muscle
cells (VSMCs) to exogenous nitric oxide (NO). The re-
corded relaxation values were plotted as percentages of
the contraction values induced by PE.
Western blot analysis
Equal amounts of total protein extracts from cells and
tissues were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
probed with different primary antibodies as specified in
each figure legend. The specific signals were amplified by
addition of horseradish peroxidase-conjugated secondaryantibodies and visualized using an enhanced chemilumin-
escence system (Amersham). The intensity of the protein
bands was quantified using Quantity One software (Bio-
Rad, Hercules, CA, USA).
Ex vivo culture of mouse thoracic aortic strips
In another experiment, strips of the mouse descending
thoracic aortic tissues (2 mm in length) from vehicle-
treated mice fed with HFD were dissected in sterile phos-
phate buffered saline and submerged in DMEM (with
584 mg/L L-glutamine, 4500 mg/L D-glucose,110 mg/L
sodium Pyruvate, pyridoxine hydrochloride), supplemented
with 10% fetal bovine serum plus 100 IU/mL penicillin
and 100 μg/mL streptomycin. OCN (58 ng/ml), LY29
4002 (PI3K inhibitor, 10 μmol/L), or Akt inhibitor V
(API-2/triciribine, 5 μmol/L) was added individually to the
culture medium for 24 h of incubation under oxygenated
condition (95% O2,5% CO2) at 37°C. After transferring
the strips to a chamber filled with fresh Krebs solution,
changes in isometric force were measured by wire myo-
graphy [18].
Statistical analysis
All data are expressed as the mean ± standard error of the
mean (SEM) and were processed with SPSS version 16.0
software (SPSS Inc., Chicago, IL, USA). The significance
(P < 0.05) of intergroup differences was assessed by two-
tailed paired Student’s t-test or one-way ANOVA, as
appropriate.
Results
Daily injections of OCN improved lipid metabolism,
glucose tolerance, insulin sensitivity and alleviated
inflammation in ApoE-KO mice
At baseline, there was no significant difference in body
weight or FBG levels among the four groups. After 12 weeks
of experimental intervention, the OCN-treated mice fed
with HFD showed a significantly lower body weight than
the vehicle-treated mice fed with HFD (27.9 ± 0.39 vs.
31.33 ± 0.60 g, P < 0.01) (Figure 1A). Compared with the
vehicle-treated mice fed with chow diet, the OCN-treated
mice fed with chow diet had significantly lower FBG level
after 12 weeks of experimental intervention (P = 0.021).
Furthermore, the decrease of FBG was more obvious in the
OCN-treated mice fed with HFD (P < 0.01) (Figure 1B).
The effect of OCN on lipid profiles was also assessed. In
mice fed with chow diet, serum levels of TC and LDL-C
were significantly lower in the OCN-treated mice com-
pared with the vehicle-treated mice. In mice fed with HFD,
serum levels of TC, TG and LDL-C significantly decreased
in OCN-treated mice compared with the vehicle-treated
mice (all P < 0.05) (Figure 1C–F). IPGTT and ITT were
conducted to determine if intermittent administration of
OCN can affect glucose metabolism in ApoE-KO mice. In
Figure 1 Daily injections of OCN improve glucose tolerance and lipid metabolism in ApoE-KO mice. Analyses were performed in mice
injected daily with the indicated doses of OCN or with vehicle for the indicated time. During 12 weeks of experimental intervention, body weight
(A), FBG (B) was measured. After 12 weeks of experimental intervention, measurements were taken of serum lipid levels (C-F), glucose during GTT
(G-H), insulin during GTT (I-J), and glucose by ITT (K-L). Values represent mean ± SEM, 6 to 8 mice per group were analyzed. *P < 0.05, **P < 0.01,
OCN-treated mice vs. vehicle-treated mice in chow diet group; #P < 0.05, ##P < 0.01, OCN-treated mice vs. vehicle-treated mice in HFD group. HF,
high fat diet; CD, chow diet; OCN, osteocalcin; FBG, fasting blood glucose.
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showed an improving tendency of both glucose toler-
ance and insulin sensitivity (vs. vehicle-treated mice)
with no significant difference detected among the mea-
sured values in these two groups (Figure 1G, K). How-
ever, in mice fed with HFD, glucose tolerance and
insulin sensitivity of OCN-treated mice significantly
improved, compared with the vehicle-treated mice
(Figure 1H, L). In addition, insulin secretion also im-
proved in both groups of OCN-treated mice (Figure 1I, J).These results suggest that daily injections of OCN is
likely to improve glucose and lipid metabolism,all of
which are the risk factors of cardiovascular disease.
Additionally, serum levels of atherogenic inflammatory
factors were also measured. Compared with the mice
fed with chow diet, serum levels of TNF-α, IL-1α, IL-12
p70 and IL-12 p40 significantly increased in mice fed
with HFD. Furthermore, serum levels of these inflam-
matory factors significantly decreased after OCN treat-
ment in mice fed with HFD (Figure 2).
Figure 2 Serum levels of atherogenic inflammatory factors decreased in OCN-treated compared with vehicle-treated ApoE-KO mice.
(A) TNF-α (B) IL-1α (C) IL-12 p70 (D) IL-12 p40. Data were shown as mean ± SEM, 6 to 8 mice per group were analyzed. **P < 0.01 vehicle-treated
mice fed with HFD vs. vehicle-treated mice fed with chow diet; #P < 0.05, ##P < 0.01 OCN-treated mice fed with HFD vs.
vehicle-treated mice fed with HFD. HF, high fat diet; CD, chow diet; OCN, osteocalcin.
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ApoE-KO mice
Blood pressure was measured after 12 weeks of experi-
mental intervention. No significant differences were de-
tected in systolic blood pressure (SBP) when comparing
among all these four groups (Figure 3A). In mice fed with
chow diet, the OCN-treated mice only showed a decreas-
ing tendency in mean blood pressure without reaching the
level of significance. However, the OCN intervention did
lead to a significant reduction of diastolic BP (P < 0.05), as
well as mean blood pressure in mice fed with HFD. (P <
0.05) (Figure 3B-C). In addition, no significant differences
were found in the comparison of heart rate among four
groups (Figure 3D).
OCN attenuates impairment of EDR in ApoE-KO
aortic strips
Following the sacrifice of the ApoE-KO mice, the aortic
arches were taken and any adventitial fat was dissected
away before cutting the aortic arch longitudinally. The
aortic arches were stained with Oil-Red-O. All of the
ApoE-KO mice have developed atherosclerosis after
the 12th week of experimental intervention (Additionalfile 1: Figure S1). The descending thoracic aorta was used
to measure the vascular reactivity. The ACh-stimulated
EDR of aortic strips was lower in the vehicle-treated mice
fed with HFD than vehicle-treated mice fed with chow diet
(maximal relaxation (Emax) = 42.30 ± 2.95 vs. 67.43 ±
8.20%, P < 0.01). The ACh-stimulated EDR was unaltered
in the OCN-treated mice fed with chow diet. However, in
mice fed with HFD, the OCN treatment induced a signifi-
cant increase in ACh-stimulated EDR (Emax = 42.30 ± 2.95
vs. 61.34 ± 5.64%, P < 0.01) (Figure 4A-C). When incubated
with L-NAME, a NO-synthase inhibitor, the ACh-induced
vasodilatory response was predominantly abolished in
all groups (Figure 4D). Endothelium-independent vaso-
dilation was studied through the addition of SNP, a NO
donor that bypasses endogenous endothelial-cell NO pro-
duction. Since the level of SNP-stimulated NO-dependent
relaxation of VSMCs was similar among all four groups,
it appeared that neither diet nor OCN treatment af-
fected VSMC responsiveness to NO in ApoE-KO mice
(Figure 4E). These results suggest that OCN treatment
improved EDR in aortae from ApoE-KO mice fed with
HFD, without affecting endothelium-independent re-
laxations to SNP.
Figure 3 Blood pressure measured in OCN-treated and vehicle-treated ApoE-KO mice. (A) Systolic blood pressure. (B) Diastolic blood
pressure. (C) Mean blood pressure. (D) Heart rate. Values represent mean ± SEM, 6 to 8 mice per group were analyzed. #P < 0.05, OCN-treated
mice fed with HFD vs. vehicle-treated mice fed with HFD. HF, high fat diet; CD, chow diet; OCN, osteocalcin.
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aortic strips
To investigate the mechanism of modulating vascular
function in ApoE-KO mice treated with OCN, total and
phosphorylated PI3K, Akt and eNOS expression were de-
tected. As shown in Figure 5, OCN treatment significantly
increased phosphorylation of PI3K, Akt and eNOS in both
chow diet group and HFD group (all P < 0.05).
OCN increases eNOS levels in HUVECs through activation
of the Akt/eNOS pathway
To determine the effect of OCN on Akt/eNOS pathway
in vitro, the phosphorylation of Akt and eNOS was exam-
ined in the OCN-treated and untreated HUVECs. Incuba-
tion of the HUVECs with OCN (100 ng/ml) significantly
increased Akt phosphorylation and eNOS phosphorylation
in a time dependent manner (Figure 6A-C). Concerning
the dose-related situation, incubation of HUVECs for 1 h
with various concentrations of OCN demonstrated that
Akt phosphorylation and eNOS phosphorylation were
gradually increased after treatment with 30, 60, 100,150 ng/ml of OCN (Figure 6D-F). Thus, OCN may acti-
vate Akt/eNOS pathway in HUVECs.The beneficial effect of OCN on EDR in ApoE-KO mice
requires the activation of the PI3K/Akt signaling pathway
To investigate whether the PI3K/Akt pathway is re-
quired for the effect of OCN on EDR, PI3K inhibitor
(LY294002) and Akt inhibitor V were applied in the
medium for descending thoracic aortic strips. OCN
treatment markedly improved the HFD-related impair-
ment of EDR in descending thoracic aortic strips from
ApoE-KO mice (Figure 7A). Coincubation with LY294002
(10 μmol/L) or Akt inhibitor V (5 μmol/L) could antago-
nized this beneficial effect, as well as inhibited the OCN
treatment-related increases in eNOS phosphorylation at
Ser1177 and Akt phosphorylation at Ser473 (Figure 7B-
D). Taken together, these observations suggested that the
mechanism underlying OCN’s protective effect on vascu-
lar function requires the activation of the PI3K/Akt signal-
ing pathway.
Figure 4 Effect of OCN on EDR in descending thoracic aortic strips of ApoE-KO mice. (A–B) ACh-mediated EDR. (C) Maximal relaxation
values. (D) ACh-induced EDR in the presence of L-NAME. (E) Endothelium-independent relaxations to SNP. Values represent mean ± SEM, 6 to 8
mice per group were analyzed. **P < 0.01 vehicle-treated mice fed with HFD vs. vehicle-treated mice fed with chow diet; #P < 0.05, ##P < 0.01
OCN-treated mice vs. vehicle-treated mice in HFD group. HF, high fat diet; CD, chow diet; EDR, endothelium-dependent relaxation;
OCN, osteocalcin.
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This study has demonstrated that daily injections of OCN
produced significant effects on glucose and lipid metabol-
ism, as well as improving insulin sensitivity, in ApoE-KO
mice, all of which represent risk factors of cardiovascular
disease. Moreover, vascular EDR was significantly im-
proved in thoracic aorta specimens from the OCN-treated
ApoE-KO mice fed a high fat diet. Following incubation of
the HUVECs or thoracic aortic strips with OCN, eNOS
phosphorylation was significantly increased and HFD-related impairment of EDR was attenuated. It was deter-
mined that the protective effect of OCN was mediated, at
least in part, by the activation of PI3K/Akt signaling path-
way, which was consistent with the research of Jung et al.
[15]. These results suggest that OCN plays an important
role in modulating endothelial function in vivo.
Previous studies have shown that, in accord with the
present study, the osteoblast-derived protein, OCN, af-
fects lipid and glucose metabolic regulation in mice. In
the current study of ApoE-KO mice, the daily injections
Figure 5 Effect of OCN on PI3K, Akt and eNOS phosphorylation in descending thoracic aortic strips of ApoE-KO mice. (A) Representative
Western blot to show the expression of PI3K, phosphorylated PI3K, Akt, phosphorylated Akt, eNOS, phosphorylated eNOS. (B) Effect of OCN on
PI3K phosphorylation. (C) Effect of OCN on Akt phosphorylation. (D) Effect of OCN on eNOS phosphorylation. Values represent mean ± SEM, 6 to 8
mice per group were analyzed. *P < 0.05, **P < 0.01, OCN-treated mice vs. vehicle-treated mice in chow diet group; #P < 0.05, ##P < 0.01, OCN-treated
mice vs. vehicle-treated mice in HFD group. HF, high fat diet; CD, chow diet; OCN, osteocalcin.
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lipids, and an increase in insulin secretion regardless of diet
composition. Although the OCN injections had no signifi-
cant effects on glucose tolerance and insulin sensitivity in
the ApoE-KO mice on a chow diet, they did improve glu-
cose tolerance and insulin sensitivity in ApoE-KO mice on
a HFD. This suggests that intermittent injections of OCN
have a more profound effect in mice with already altered
insulin sensitivity [19]. Systemic metabolic abnormalities,
such as dyslipidemia, hyperglycemia and insulin resistance,
are important risk factors of cardiovascular disease [20,21].
Hypercholesterolemia is one of the characteristics of
ApoE-KO mice [22]. Substantial clinical and experimental
evidence has suggested that both hyperglycemia and dys-
lipidemia contribute to endothelial cell dysfunction. Hyper-
glycemia causes an accelerated formation of advanced
glycation end-products and mitochondrial overproduction
of reactive oxygen species. Dyslipidemia also strongly and
directly enhances monocyte adhesion to endothelium. Both
alterations can result in vascular injury and endothelial
damage. Given that OCN can ameliorate dyslipidemia and
impaired glucose metabolism, it may well constitute a pro-
tective factor for vascular disease. TNF-α, IL-1α and IL-12
are known as pathogenic factors during the developmentof atherosclerosis. Our results suggested that OCN may
also play a role in alleviating chronic inflammation in
ApoE-KO mice. In addition, several clinical studies have
reported a significantly inverse correlation between OCN
and blood pressure [23,24]. In the present study, a signifi-
cant vascular protective effect of OCN, through its lower-
ing of mean BP and diastolic BP, was found in ApoE-KO
mice fed the HFD.
The endothelium plays an important role in maintaining
vascular homeostasis by synthesizing and releasing several
vasodilators, including NO and endothelium-derived hy-
perpolarizing factor (EDHF) [25]. In mouse aorta, NO is
the sole endothelial-derived mediator [26]. Substantial
clinical and experimental evidence suggests that endothe-
lial dysfunction is an early marker for the initiation and
progression of atherosclerosis [27]. ApoE-KO mice, as in
the present study, are one of the most widely used animal
models of atherosclerosis [28-30]. Endothelial dysfunction
has been demonstrated in the aorta of ApoE-KO mice fed
a western diet and is characterized by impaired ACh-
induced endothelium-mediated aortic vasodilation. In ac-
cord with previous studies, our research found a reduced
EDR to ACh in the aorta of ApoE-KO mice fed with HFD;
this result serves as an important indicator of vascular
Figure 6 Effect of OCN on the phosphorylation of Akt and eNOS in cultured HUVECs. (A) HUVECs incubated with 100 ng/mL OCN or
vehicle for the indicated times. (B) The effects of OCN on Akt phosphorylation. (C) The effects of OCN on eNOS phosphorylation. (D) HUVECs
incubated with the indicated concentrations of OCN or vehicle for 1 h. (E) The effects of OCN on Akt phosphorylation. (F) The effects of OCN on
eNOS phosphorylation. Mean ± SEM of four independent experiments are plotted. *P < 0.05, **P < 0.01 vs. control group. OCN, osteocalcin.
Dou et al. Cardiovascular Diabetology 2014, 13:74 Page 9 of 12
http://www.cardiab.com/content/13/1/74dysfunction. Furthermore, an increased EDR to ACh
was demonstrated in the OCN-treated HFD group. By
contrast, the phenomenon was not observed in mice fed
with chow diet. Previous studies suggested that the ex-
pression of total Akt significantly increased in HFD sta-
tus, which may indicate a compensatory or adaptive
mechanism in obese mice [31-33]. This might explain
why OCN had a more significant effect on EDR in mice
fed with HFD through the regulation of the Akt/eNOS-dependent pathway. Application of L-NAME abolished
EDR in all of the ApoE-KO mice, regardless of diet
composition, similar to the findings of other researchers
[34]. However, OCN did not appear to affect the ability
of VSMCs to respond to NO. Thus, OCN may play a
positive role in endothelial vasodilatory function and
this beneficial effect may result from, at least partially,
its favorable modulation of glucose and lipid metabol-
ism by way of its protective effect against endothelial
Figure 7 Effect of OCN on ACh-stimulated EDR and PI3K/Akt signaling pathway in descending thoracic aortic strips of ApoE-KO mice
fed with HFD. (A) Beneficial effect of OCN treatment for 24 h on EDR. (B) OCN-mediated changes in phosphorylation of eNOS and Akt in the
presence of PI3K inhibitor LY294002 or Akt inhibitor V. (C) The effects of OCN, LY294002 and Akt inhibitor V on Akt phosphorylation. (D) The
effects of OCN, LY294002 and Akt inhibitor V on eNOS phosphorylation. Values represent mean ± SEM, n = 5-6. #P < 0.05, ##P < 0.01, HF +
OCN-treated + LY294002 vs. HF + OCN-treated group; *P < 0.05, **P < 0.01, HF + OCN-treated + Akt inhibitor V vs. HF + OCN-treated group.
HF, high fat diet; EDR, endothelium-dependent relaxation; OCN, osteocalcin.
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tabolism disorders.
This study also sought to determine the possible mech-
anism that underlies the relationship between OCN and
vascular EDR. Altered eNOS-NO signaling is a common
feature observed in animal models exhibiting impaired
endothelial function [35-38]. Phosphorylation at Ser1177
is necessary for the maximal activation of eNOS and re-
sults in optimal NO production [39]. In the present study,expression of P-eNOS and total eNOS was increased in
descending thoracic aortic strips of OCN-treated ApoE-
KO mice fed with HFD, compared with the vehicle-
treated ApoE-KO mice fed with HFD. In addition, similar
results were found in OCN-treated HUVECs, and this
in vitro finding agreed with those of a previous study by
this group [15]. Collectively, these results suggest that
eNOS-NO signaling may contribute to the OCN-mediated
modulation of vasorelaxation in ApoE-KO mice.
Dou et al. Cardiovascular Diabetology 2014, 13:74 Page 11 of 12
http://www.cardiab.com/content/13/1/74In the endothelium, PI3K/Akt signaling mostly acts as a
positive regulator of endothelial NO synthase, which gen-
erates NO through the NADPH-dependent oxidation of
L-arginine [40,41]. Regarding the regulation of eNOS by
PI3K/Akt signaling, it has previously been shown that acti-
vated Akt phosphorylates eNOS on Ser1177, enhancing
both basal and stimulated eNOS enzyme activity, and
thereby NO release [42,43]. In contrast, loss of the Akt1
subtype in the vessel wall is associated with reduced eNOS
phosphorylation [44,45]. In the present study, phosphoryl-
ation of both Akt and eNOS was significantly increased in
HUVECs in response to OCN treatment. Furthermore, a
beneficial effect of OCN was observed using an ex vivo
organ culture of isolated mouse aortic strips, which was
attenuated upon coincubation with a PI3K or Akt inhibi-
tor. These results suggest that OCN may protect vascular
endothelial cell from impairment, in part, by activating the
PI3K/Akt signaling pathway.
Conclusions
In summary, the current study supported that daily injec-
tions of OCN is likely to reduce the risk of cardiovascular
disease, as it improves glucose and lipid metabolism. Fur-
thermore, a protective effect of OCN on vascular EDR was
demonstrated. Such beneficial activities of OCN, which lead
to an increase of eNOS phosphorylation, required the
activation of the PI3K/Akt/eNOS signaling pathway. These
novel findings may help to enhance the prospective of
OCN in combating vascular dysfunction in atherosclerosis.Additional file
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